About this Journal Submit a Manuscript Table of Contents
Parkinson’s Disease
Volume 2011 (2011), Article ID 624764, 6 pages
http://dx.doi.org/10.4061/2011/624764
Research Article

Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients

1Parkinson Institute, Istituti Clinici di Perfezionamento (ICP), via Bignami 1, 20126 Milan, Italy
2Istituto Auxologico Italiano, via Zucchi 18, 20095 Cusano Milanino, Milan, Italy
3Centro Analisi Monza (CAM), via Missori 9, 20052 Monza, Italy

Received 10 January 2011; Revised 21 March 2011; Accepted 24 April 2011

Academic Editor: Francisco Grandas

Copyright © 2011 Erica Cassani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Patients with advanced Parkinson's disease (PD) experience body weight loss and reductions in the most common cardiovascular risk factors. At present, the pathogenetic mechanisms involved have not been elucidated. Increased serum concentrations of adiponectin, which possesses antiatherogenic and anti-inflammatory properties, are associated with a reduction in cardiovascular risk. The objective of this study was to determine adiponectin serum concentrations in PD patients. Thirty PD patients underwent a full nutritional status assessment, including the determination of adiponectin serum concentrations. Mean ± SD adiponectin concentrations were 9.59 ± 5.9 μg/mL (interquartile range: 5.92–12.9 μg/mL). In PD patients, adiponectin serum levels were similar to those in normal-weight, healthy, young subjects and significantly higher than that in an aged-matched group of morbidly obese subjects. Further studies are warranted to establish the role of adiponectin in the management of PD patients.